Abstract 6636: Therapy with BXCL701 (B), a DPP8, DPP9, DPPIV and FAP inhibitor, in combination with anti-PD1 antibody (PD1) in a syngeneic murine pancreatic ductal adenocarcinoma (PDAC) model improves treatment outcomes and induces intratumoral NK cell infiltrates and a marked reduction in tumor stromal fibrosis

Shangzi Wang; Allison Fitzgerald; Reham Ajina; Sandra A. Jablonsk; Louis M. Weiner; John MacDougall; Veena Agarwal; Vince J. O'Neill

doi:10.1158/1538-7445.AM2020-6636

Immunology

Abstract 6636: Therapy with BXCL701 (B), a DPP8, DPP9, DPPIV and FAP inhibitor, in combination with anti-PD1 antibody (PD1) in a syngeneic murine pancreatic ductal adenocarcinoma (PDAC) model improves treatment outcomes and induces intratumoral NK cell infiltrates and a marked reduction in tumor stromal fibrosis

Shangzi Wang, Allison Fitzgerald, Reham Ajina, Sandra A. Jablonsk, Louis M. Weiner, John MacDougall, Veena Agarwal and Vince J. O'Neill

Shangzi Wang

1Georgetown Lombardi Comprehensive Cancer Center, Washington, DC;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Allison Fitzgerald

1Georgetown Lombardi Comprehensive Cancer Center, Washington, DC;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Reham Ajina

1Georgetown Lombardi Comprehensive Cancer Center, Washington, DC;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sandra A. Jablonsk

1Georgetown Lombardi Comprehensive Cancer Center, Washington, DC;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Louis M. Weiner

1Georgetown Lombardi Comprehensive Cancer Center, Washington, DC;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

John MacDougall

2BioXcel Therapeutics, New Haven, CT.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Veena Agarwal

2BioXcel Therapeutics, New Haven, CT.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vince J. O'Neill

2BioXcel Therapeutics, New Haven, CT.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

DOI: 10.1158/1538-7445.AM2020-6636 Published August 2020

Article
Info & Metrics

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: August 2020 to January 2021

	Abstract	Full-text HTML	PDF
Total	177	0	0

Cited By

Article Information

Volume 80, Issue 16 Supplement, pp. 6636

DOI

https://doi.org/10.1158/1538-7445.AM2020-6636

Published By

American Association for Cancer Research

Print ISSN

0008-5472

Online ISSN

1538-7445

Author Information

Shangzi Wang1,
Allison Fitzgerald1,
Reham Ajina1,
Sandra A. Jablonsk1,
Louis M. Weiner1,
John MacDougall2,
Veena Agarwal2, and
Vince J. O'Neill2

¹Georgetown Lombardi Comprehensive Cancer Center, Washington, DC;
²BioXcel Therapeutics, New Haven, CT.

August 2020
Volume 80, Issue 16 Supplement

Table of Contents

Search for this keyword

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Abstract 6636: Therapy with BXCL701 (B), a DPP8, DPP9, DPPIV and FAP inhibitor, in combination with anti-PD1 antibody (PD1) in a syngeneic murine pancreatic ductal adenocarcinoma (PDAC) model improves treatment outcomes and induces intratumoral NK cell i…

Message Subject (Your Name) has forwarded a page to you from Cancer Research

Message Body (Your Name) thought you would be interested in this article in Cancer Research.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Abstract 6636: Therapy with BXCL701 (B), a DPP8, DPP9, DPPIV and FAP inhibitor, in combination with anti-PD1 antibody (PD1) in a syngeneic murine pancreatic ductal adenocarcinoma (PDAC) model improves treatment outcomes and induces intratumoral NK cell infiltrates and a marked reduction in tumor stromal fibrosis

Shangzi Wang, Allison Fitzgerald, Reham Ajina, Sandra A. Jablonsk, Louis M. Weiner, John MacDougall, Veena Agarwal and Vince J. O'Neill

Cancer Res August 15 2020 (80) (16 Supplement) 6636; DOI: 10.1158/1538-7445.AM2020-6636

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Shangzi Wang, Allison Fitzgerald, Reham Ajina, Sandra A. Jablonsk, Louis M. Weiner, John MacDougall, Veena Agarwal and Vince J. O'Neill

Cancer Res August 15 2020 (80) (16 Supplement) 6636; DOI: 10.1158/1538-7445.AM2020-6636

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Info & Metrics

Cited By...

Immunology

Abstract 6699: CUE-102 Immuno-STATs for selective targeting and expansion of WT1-specific T cells for the treatment of HLA-A02⁺and/or HLA-A24⁺patients with WT1⁺ malignancies
Abstract 6641: In situ immunization with the TLR9-agonist CMP-001 enhances anti-PD1 therapy in head and neck tumors
Abstract 6681: Inhibition of LSD1 using the reversible inhibitor SP2577 promotes Interferon dependent anti-tumor response in adrenocortical carcinoma

Show more Immunology

Poster Presentations - Proffered Abstracts

Abstract PO-048: MicroRNA-10b is a regulator of cellular viability and proliferation in fibrolamellar carcinoma
Abstract PO-055: Pan-cancer metabolic profiling of the tumor microenvironment
Abstract PO-041: Genome-wide CRISPR/Cas9 screen reveals mitochondrial gene mutation as a driver for drug resistance in Ewing sarcoma

Show more Poster Presentations - Proffered Abstracts

Poster Presentations - Combination Immunotherapies

Abstract 6630: Synergistic immuno photothermal nanotherapy (SYMPHONY) for combination cancer therapy
Abstract 6645: Anti-EGF antibodies significantly improve the activity of RET, BRAF, MEK and PI3K kinase inhibitors in preclinical models
Abstract 6641: In situ immunization with the TLR9-agonist CMP-001 enhances anti-PD1 therapy in head and neck tumors

Show more Poster Presentations - Combination Immunotherapies

Main menu

User menu

Search

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: August 2020 to January 2021

Cited By

Article Information

Author Information

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Immunology

Poster Presentations - Proffered Abstracts

Poster Presentations - Combination Immunotherapies

Articles

Info for

About Cancer Research